ArticleChest2021
Adherence to Asthma Biologics: Implications for Patient Selection, Step Therapy, and Outcomes.
Article in Chest, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Digital interventions to improve adherence to maintenance medication in asthma.The Cochrane database of systematic reviews · 2022Pooled it
- Consistent adherence to biologic therapies is critical for improving outcomes in asthma.The journal of allergy and clinical immunology. Global · 2026Article
- The Adherence Paradox in Uncontrolled Moderate-To-Severe Asthma: A Qualitative Study of Patient Experiences and Unmet Needs.Research in nursing & health · 2026Article
- Relationship between knowledge, adherence-related behaviors and self-management with response to monoclonal antibody therapy in patients with severe asthma.Scientific reports · 2026Article
- Long-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain.Journal of clinical medicine · 2026Article
- Associations Between Social Determinants of Health and Adherence to Biologic Therapies in Patients with Severe Asthma: Real-World Evidence from a Large US Claims Analysis.Journal of asthma and allergy · 2026Article
- Adherence to Biologic Therapies is Associated with Improved Clinical Outcomes and Reduced Healthcare Resource Utilization in Patients with Severe Asthma in Japan.Journal of asthma and allergy · 2026Article
- Depemokimab and the twice-yearly regimen: pharmacological implications and therapeutic positioning in severe eosinophilic respiratory diseases.Frontiers in immunology · 2026Review
- Assessment of Inhaled Corticosteroid Adherence in Adults with Severe Asthma Receiving Biologic Therapy: A Retrospective Observational Study.Journal of asthma and allergy · 2026Article
- Psychological and Related Factors Influencing Adherence to Biologic Therapies in Asthma: A Scoping Review.Current allergy and asthma reports · 2025Article
- Real-World Adherence to Biologic Therapy for Severe Asthma in Children.The journal of allergy and clinical immunology. In practice · 2025Article
- The Impact of Biological Therapies and the Significance of Their Adherence on Asthma Outcomes in a Single Tertiary Asthma Center.Journal of asthma and allergy · 2025Article
- Unlocking Better Asthma Control: A Narrative Review of Adherence to Asthma Therapy and Innovative Monitoring Solutions.Journal of clinical medicine · 2024Review
- Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Article
- Article
- The clinical impact of adherence to therapy in airways disease.Breathe (Sheffield, England) · 2021Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundLittle is known about adherence to asthma biologics. RESEARCH QUESTION: Is adherence to inhaled corticosteroid (ICS) associated with subsequent asthma biologic adherence? STUDY DESIGN AND
methodsWe analyzed individuals with asthma who started asthma biologics in the OptumLab Data Warehouse and used that data until October 2019. We calculated proportion days covered (PDC) for ICS ± long-acting β-agonists in the 6 months before and after asthma biologics were started and asthma biologic PDC for the first 6 months of use. We performed a multivariable analysis to identify factors associated with asthma biologic PDC ≥0.75, ICS PDC ≥0.75 during the 6-month period after asthma biologic were started, and achievement of a ≥50% reduction in asthma exacerbations during the first 6 months of asthma biologic use.
resultsWe identified 5,319 people who started asthma biologics. The mean PDC for asthma biologics was 0.76 (95% CI, 0.75-0.77) in the first 6 months after starting, higher than the mean PDCs for ICS in the 6 months before (0.44 [95% CI, 0.43-0.45]) and after (0.40 [95% CI, 0.39-0.40]) starting the asthma biologic. PDC ≥0.75 for ICS 6 months before index biologic use is associated with PDC for asthma biologics ≥0.75 (OR, 1.25; 95% CI, 1.10-1.43) and for ICS during the first 6 months of biologic use (OR, 9.93; 95% CI, 8.55-11.53). Neither ICS PDC ≥0.75 (OR, 0.92; 95% CI, 0.74-1.14) nor asthma biologic PDC ≥0.75 (OR, 1.15; 95% CI, 0.97-1.36) is associated with a statistically significant reduction in asthma exacerbations during the first 6 months of asthma biologic use among people with any exacerbation in the 6 months before first use.
interpretationAdherence to asthma biologic is higher than to ICS and is associated with different factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.